Top canonical pathways associated with acute phase of STEMI.

<p>Ingenuity Pathway Analysis of gene sets differentially expressed on the first day of myocardial infarction versus 6 months after MI or versus control group was performed. Functional categories are represented on the x-axis. The significance is expressed as the negative exponent on the p-value calculated for each function on the y-axis of the diagram, increasing with bar height.</p

Validation of microarray data using qRT-PCR.

***<p>p<0.001; **p<0.01; *p<0.05; ^NS – not significant.</p><p>All genes abbreviations are explained in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0050054#pone-0050054-t002" target="_blank">Table 2</a>.</p

Differentially expressed genes common to both analyses: admission versus control and discharge versus control.

<p>Differentially expressed genes common to both analyses: admission versus control and discharge versus control.</p

Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.

<p>Differentially expressed genes common to both analyses: admission versus 6 months after MI and admission versus control.</p

Expression data from microarray experiments for chosen genes.

<p>The y-axis represents the log2 normalized intensity of the gene and the x-axis represents analyzed groups. The line inside the box and whiskers represents the median of the samples in a group. Points present relative expression levels in individual patients at admission (blue), at discharge (green), 6 month after MI (violet) and from control group (red). Numbers indicate the coded identity of a particular patient. SOCS3– suppressor of cytokine signaling 3; ST14– MT-SP1/matriptase; AQP 9– aquaporin 9; MYBL1– v-myb myeloblastosis viral oncogene homolog (avian)-like 1; STAB1– stabilin 1; ASGR2– asialoglycoprotein receptor 2.</p

Major characteristics of the study and control groups.

*<p>Mean ± Standard Deviation.</p>**<p>number (%);</p><p>NA – not applicable.</p

Additional file 1: Table S1. of Two novel C-terminal frameshift mutations in the β-globin gene lead to rapid mRNA decay

Sequences of the primers. (DOCX 13 kb

Electrochemical Capture and Release of CO₂ in Aqueous Electrolytes Using an Organic Semiconductor Electrode

Developing efficient methods for capture and controlled release of carbon dioxide is crucial to any carbon capture and utilization technology. Herein we present an approach using an organic semiconductor electrode to electrochemically capture dissolved CO₂ in aqueous electrolytes. The process relies on electrochemical reduction of a thin film of a naphthalene bisimide derivative, 2,7-bis­(4-(2-(2-ethylhexyl)­thiazol-4-yl)­phenyl)­benzo­[lmn]­[3,8]­phenanthroline-1,3,6,8­(2H,7H)-tetraone (NBIT). This molecule is specifically tailored to afford one-electron reversible and one-electron quasi-reversible reduction in aqueous conditions while not dissolving or degrading. The reduced NBIT reacts with CO₂ to form a stable semicarbonate salt, which can be subsequently oxidized electrochemically to release CO₂. The semicarbonate structure is confirmed by in situ IR spectroelectrochemistry. This process of capturing and releasing carbon dioxide can be realized in an oxygen-free environment under ambient pressure and temperature, with uptake efficiency for CO₂ capture of ∼2.3 mmol g^–1. This is on par with the best solution-phase amine chemical capture technologies available today